Alamar Biosciences Inc. Common Stock (ALMR)
StalwartFairStock Score: 20/100 — RISKY
Key Financials
| Current Price | $21.54 |
| Market Cap | $1.6B |
| P/E Ratio | -33.14 |
| ROE | -33.58% |
| Dividend Yield | —% |
| Sector | Healthcare |
AI Analysis
Alamar Biosciences Inc. Common Stock is a micro-cap healthcare company valued at $1.6 billion. Revenue stands at $87 million. From a quality standpoint, Alamar shows negative ROE indicating losses and elevated leverage at 1.85x D/E. Our composite FairStock Score of 20/100 reflects below-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.
Bull Case
Improving fundamentals and sector tailwinds could drive meaningful earnings growth, compressing the effective multiple for patient investors. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.
Bear Case
Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.
Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer